Q94 is a selective PAR1 antagonist and allosteric modulator that selectively block PAR(1) /Gα(q) interaction and signalling.
Q94 caused an approximately fourfold decrease in thrombin EC50 value, did not alter the Ca(2+) response mediated by a PAR(2) activating peptide.
Q94 suppressed the doxorubicin-induced increase in activities of caspase-9 and caspase-3 in podocytes.
Q94 treatment significantly attenuated periodic acid-Schiff and desmin staining, indicators of podocyte injury, and also decreased glomerular levels of podocin and nephrin in mouse model of nephropathy.
